-transparent.png){kind=logo}
Ninety-one hay fever patients received either 0.5 mg/kg oxatomide b.i.d. or 0.4 mg/kg diphenhydramine b.i.d. in a two-month double-blind study. If necessary this dose could be doubled. The results showed that fewer oxatomide patients needed to double this starting dose and to use a nasal spray. Oxatomide proved to be more effective than diphenhydramine in limiting the severity of the hay fever attacks, as evidenced by the findings that oxatomide patients had fewer complaint-days, and that more of these patients were rated by the investigators to have excellent or good results. Apart from daytime fatigue, transient in several patients, no oxatomide-induced side-effects were found.
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
September 1981,
Clinical allergy,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
January 1980,
Plucne bolesti i tuberkuloza,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
June 1984,
Xenobiotica; the fate of foreign compounds in biological systems,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
July 1988,
Clinical allergy,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
January 1985,
Dermatologica,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
December 1989,
Allergie et immunologie,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
August 1977,
Acta allergologica,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
May 1981,
Allergy,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
June 1972,
Schweizerische medizinische Wochenschrift,
W J van der Bijl, and
R Cordier, and
E A van Dishoeck, and
W De Proost, and
E Vannieuwenhuyse
May 1972,
The Practitioner,
